10/518184

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE DTO! Rec'd PCI/PIC 1 6 DEC 2004

Application No.:

Based on PCT/JP03/007741

Filed:

Intl. Filing 18 JUNE 2003

1st Inventor:

Tatsuya WATANABE

For:

Preventing/Treating Agent for Bone or Joint Diseases

Atty. Dkt. No.

3057 US0P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

MAIL STOP PCT P.O. Box 1450 Commissioner for Patents Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and 08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Dated 7/16/8

(847) 383-3372

(847) 383-3391

Respectfully submitted

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| Substitute for form 1449/PTO | Complete if Known | | | |
|-----------------------------------|------------------------|--------------------------|--|--|
| | Application Number | Based on PCT/JP03/007741 | | |
| INFORMATION DISCLOSURE | Filing Date | Intl Date 18 JUNE 2003 | | |
| | First Named Inventor | Tatsuya WATANABE | | |
| STATEMENT BY APPLICANT | Art Unit | tba | | |
| (Use as many sheets as necessary) | Examiner Name | tba | | |
| Sheet 1 of 2 | Attorney Docket Number | 3057 US0P | | |

| Examiner | Cite | Document Number | U. S. PATENT D | Name of Patentee or | Pages, Columns, Lines, Where |
|-----------|--|---|--|-----------------------------|---|
| Initials* | Cite No.1 | Number-Kind Code ^{2 (# known)} | MM-DD-YYYY | Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | US- | | | |
| | | | | | |
| |] | US- | | | 1 |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | , |
| | | US- | | · | |
| | | US- | | | |
| | | US- | | | |
| | | US- | 1 | | |
| | | US- | | | |
| | <u> </u> | US- | | | |
| | | US- | | | |
| | | US- | | | |

| | | FOREIG | N PATENT DOCL | JMENTS | | |
|-----------------------|--------------|---|---------------------|--|---|-----|
| Examiner Initials* | Cite No.1 | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages | |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | MM-DD-YYYY | | Or Relevant Figures Appear | T°. |
| | A1 | WO 01/44268 A1 | 06/21/2001 | Sterix Limited | | |
| | A2 | WO 99/64013 | 12/16/1999 | Sterix Limited | | |
| | A3 | WO 99/52890 | 10/21/1999 | Novartis-Erfindungen | | |
| | A4 | WO 01/55411 A2 | 08/02/2001 | Millenium Pharmaceuticals | | |
| | | | | | | |
| | | | | | | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DT 6 18 18 4 DT 6 18 18 4 DEC'd PCT/PTC ptd 56.0 DEC 3, 2004

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent AND Trademark OFFICE; U.S. DEPARTMENT OF COMMERCE

U.S. Patent AND Trademark OFFICE; U.S. DEPARTMENT OF COMMERCE

U.S. Patent AND Trademark OFFICE; U.S. DEPARTMENT OF COMMERCE

U.S. Patent AND Trademark OFFICE; U.S. DEPARTMENT OF COMMERCE

U.S. Patent AND Trademark OFFICE; U.S. DE

| Substitute for form 1449/PTO | Complete if Known | | |
|-----------------------------------|------------------------|--------------------------|--|
| 9333440 151 151111 174551 10 | Application Number | Based on PCT/JP03/007741 | |
| INFORMATION DISCLOSURE | Filing Date | Intl Date 18 JUNE 2003 | |
| STATEMENT BY APPLICANT | First Named Inventor | Tatsuya WATANABE | |
| (Use as many sheets as necessary) | Art Unit | tba | |
| (Use as many sheets as necessary) | Examiner Name | tba | |
| Sheet 2 of 2 | Attorney Docket Number | 3057 US0P | |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | A 5 | ANDREW M. HO, et al., "Role of the Mouse ank Gene in Control of Tissue Calcification and Arthritis", Science, (2000), pp. 265-270, Vol. 289, No. 14 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | |
|-----------|------------|------|
| Examiner | Date | |
| Signature | Considered | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.